Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center

Toms Vengaloor Thomas 1, Mary R. Nittala 1, Eldrin Bhanat 1, Ashley A. Albert 1, Srinivasan Vijayakumar 1

1. Radiation Oncology, University of Mississippi Medical Center, Jackson, USA

Corresponding author: Toms Vengaloor Thomas, tvthomas@umc.edu

Abstract

Introduction

Due to conflicting data in the literature, there is a continuing debate on whether advanced hypopharyngeal carcinoma patients should be treated with definitive surgery or chemoradiotherapy. The purpose of this study is to evaluate the management and outcomes of advanced hypopharyngeal carcinoma in a tertiary care institution over the last 25 years.

Methods

An Institutional Review Board (IRB)-approved and HIPPA-compliant retrospective analysis was performed of patients with advanced-stage squamous cell carcinoma of the hypopharynx treated at our institution between January 1994 and December 2018. Data regarding demographics, stage, treatment, and follow-up were collected.

Results

This study included a total of 103 advanced stage hypopharyngeal cancer patients. The median age for this cohort is 61 years (range: 41-88, SD 9.3). Of the total 103 eligible patients treated, 92 (89.5%) were male and 11 (10.7%) female; 61 (59.2%) were African Americans, 39 (37.9%) were Caucasians and three (2.9%) were other races. Seventeen patients (16.5%) had stage III disease, whereas 86 (83.5%) patients were diagnosed with Stage IV A or B disease. Seventy-two patients (69.9%) were treated with definitive chemoradiotherapy (ChemoRT group), and 31 patients (30.1%) underwent primary surgery with or without adjuvant treatments (Surgery group). The two treatment groups were similar in terms of age, gender, ethnicity, alcohol status, N staging, and subsites but were significantly different for smoking status (p = 0.035) and T staging (p = 0.024). The median follow-up was 17 months. The median survival of the overall cohort was 26 months, and five-year overall survival was 25.5%. The median survival was found to be significantly better for the surgery group as compared to the definitive chemoradiotherapy group (43 months vs 16 months, p = 0.049). The five-year overall survival (OS; 41.5% vs 18.5%, p = 0.049) and disease-free survival (DFS; 75.3% vs 56%, p = 0.029) were significantly better for patients in the surgery group compared to the chemoradiotherapy group. On multivariate Cox-regression analysis, lymph nodal status (HR = 1.27, CI: 1.00-1.62, p = 0.047) and chemoradiation treatment (HR = 1.82, CI: 1.00-3.29, p = 0.049) were associated with higher risk of mortality.

Conclusion

In our single institutional experience of advanced hypopharyngeal carcinoma management, the five-year overall survival rate was found to be 25.5% and was the poorest among head and neck cancers. The patients with advanced hypopharyngeal cancer treated with surgery followed by adjuvant radiation or chemoradiation have significantly improved overall survival compared to those treated with definitive chemoradiotherapy. Further research warranted for early detection and better treatment to improve the cure rate in hypopharyngeal carcinoma patients.

How to cite this article

Vengaloor Thomas T, Nittala M R, Bhanat E, et al. (January 16, 2020) Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center. Cureus 12(1): e6679. DOI 10.7759/cureus.6679
chemoradiotherapy is considered the standard of care, but there is a continuing debate on the outcomes due to conflicting data [2,6,10-20]. The purpose of this study is to evaluate the management and outcomes of advanced hypopharyngeal carcinoma in a tertiary care institution in the United States over the past 25 years.

**Materials And Methods**

**Selection of patients**

The Institutional review board (IRB) of the University of Mississippi Medical Center (UMMC) approved all the investigations. The written consent was waived due to the retrospective nature of the study. Data were collected by review of patient charts from the Head and Neck Cancer database of UMMC, diagnosed between January 1994 and December 2018. Research electronic data capture (RedCap), a browser-based database tool, was used to gather and store the patient's information in password-protected computers. We identified 145 patients with hypopharyngeal cancer treated at our institution during the time frame. We collected patient demographic data, including age, sex, race, smoking history, alcohol abuse history, insurance status, and, weight at diagnosis, and tumor characteristics data including pathology, subsite, clinical-stage, the pathological stage. The TNM classification system of the American Joint Committee on Cancer 7th Edition (AJCC 7) was used for staging. The data on management options including surgery, adjuvant radiation, adjuvant chemoradiation, definitive chemoradiation, salvage treatments, palliative chemotherapy, or hospice care were also collected from the patient charts and MOSAIQ record and verify system in radiation oncology. The institutional cancer registry provided the data on follow up and vital statistics of the patients. The exclusion criteria were early-stage disease (stages I or II), metastatic disease at presentation (stage IV), treatment with palliative intent, or hospice care. One hundred and three patients met the inclusion criteria. We excluded six patients due to early-stage disease, nine patients due to metastatic disease at presentation, and twenty-seven patients due to treatment with palliative intent (Figure 1).

**FIGURE 1:** Cohort selection – flow chart for advanced hypopharynx cancer
Surgical management
The patients with advanced disease (Stage III, IV A) underwent total laryngectomy and partial pharyngectomy with bilateral or unilateral neck dissection if they were not candidates for laryngeal preservation. Thirty-one (30.1%) patients underwent primary surgical management. Five patients underwent surgery only, and 26 patients underwent adjuvant treatments after definitive surgery.

Radiation treatment and chemotherapy
The radiotherapy was used either as definitive or as adjuvant treatment. Definitive concurrent chemoradiotherapy was delivered as part of laryngeal preservation for advanced stage (III & IV A) or patients with the unresectable disease (Stage IV B). In all, 72 patients (69.9%) underwent definitive chemoradiation to a dose of 7000 cGy. The patients were treated with adjuvant radiation or adjuvant chemoradiation after definitive surgery, depending on risk factors. Eighteen patients received adjuvant radiation treatment, and eight patients underwent adjuvant chemoradiotherapy to a dose of 60-66Gy. The patients had been treated with three-dimensional (3D) treatment planning techniques before 2008 and switched to intensity-modulated radiation treatment (IMRT) technique as IMRT became available in 2008. All of the radiation treatment plans were evaluated by departmental peer review before the initiation of treatment [21-23]. The choice of chemotherapy administered concurrently with radiation was at the discretion of the treating medical oncologist. The most commonly used regimen was weekly cisplatin. Carboplatin or cetuximab was the other systemic therapy options if the patient was not cisplatin eligible due to comorbidities, mainly renal dysfunction.

Statistical analysis
We used SPSS 24.0 software for data analysis. Kaplan-Meier method was used to evaluate overall survival (OS), disease-free survival (DFS), and the log-rank test measured comparison between different treatment groups. The patients who were alive at the time of the last follow up were categorized as censored cases. The multivariate Cox regression model determined the co-variables associated with the OS and DFS. Hazards ratio (HR) was used to estimate time to event outcome with associated 95% confidence intervals (CIs), and p-values ≤ 0.05 were considered statistically significant.

Results
Patient characteristics
This study included a total of 103 advanced stage hypopharyngeal cancer patients. The median age for this cohort is 61 years (range: 41-88, SD: 9.5). Of the total 103 eligible patients treated, 92 (89.3%) were males and 11 (10.7%) were females. Sixty-one (59.2%) patients were African Americans, 39 (37.9%) were Caucasians and, three (2.9%) were other races. Seventeen patients (16.5%) had stage III disease, whereas 86 (83.5%) patients had stage IV A or B disease. Pyriform sinus was the most commonly affected subsite (73%), followed by the posterior pharyngeal wall (10%) and post cricoid area (5%). Seventy-two (69.9%) patients underwent definitive chemoradiotherapy (ChemoRT group), and 31 (30.1%) patients underwent definitive surgery with or without adjuvant treatments (Surgery group). The patient characteristics are summarized in Table 1. The two treatment groups were similar in age, gender, ethnicity, alcohol status, N staging, and subsites but were significantly different for smoking status ($p = 0.035$) and T staging ($p = 0.024$).
|                          | All Patients | Definitive ChemoRT | Surgery | p-value |
|--------------------------|--------------|--------------------|---------|---------|
|                          | (n = 103)    | n = 72 (69.9%)     | n = 31 (30.1%) |         |
| Age, Mean (SD)           | 60.3 (9.3)   | 59.7 (9.5)         | 61.2 (8.8) | 0.508   |
| Gender/ Sex              |              |                    |         |         |
| Male                     | 92 (89.3%)   | 64 (89.9%)         | 28 (90.3%) | 0.829   |
| Female                   | 11 (10.7%)   | 8 (11.1%)          | 3 (9.7%)  |         |
| Ethnicity                |              |                    |         |         |
| Caucasians               | 39 (37.9%)   | 28 (38.9%)         | 11 (35.5%) | 0.945   |
| African Americans        | 61 (59.2%)   | 42 (58.3%)         | 19 (61.3%) |         |
| Others                   | 3 (2.9%)     | 2 (2.8%)           | 1 (3.2%)  |         |
| Smoking status           |              |                    |         | 0.035   |
| Smoker                   | 80 (77.7%)   | 60 (83.3%)         | 20 (64.5%) |         |
| Non-Smoker               | 23 (22.3%)   | 12 (16.7%)         | 11 (35.5%) |         |
| Alcohol Status           |              |                    |         | 0.98    |
| Drinker                  | 60 (58.3%)   | 42 (58.3%)         | 18 (58.1%) |         |
| Non- Drinker             | 43 (41.7%)   | 30 (41.7%)         | 13 (41.9%) |         |
| TNM Stage (III, IV)      |              |                    |         |         |
| T classification         |              |                    |         | 0.024   |
| T1                       | 8 (7.8%)     | 5 (6.9%)           | 3 (9.7%)  |         |
| T2                       | 13 (12.6%)   | 12 (16.7%)         | 1 (3.2%)  |         |
| T3                       | 17 (16.5%)   | 8 (11.1%)          | 9 (29.0%) |         |
| T4                       | 41 (39.8%)   | 33 (45.8%)         | 8 (25.8%) |         |
| Unknown                  | 24 (23.3%)   | 14 (19.4%)         | 10 (32.3%) |         |
| N Classification         |              |                    |         | 0.116   |
| N0                       | 20 (19.4%)   | 12 (16.7%)         | 8 (25.8%) |         |
| N1                       | 8 (7.8%)     | 7 (9.7%)           | 1 (3.2%)  |         |
| N2                       | 45 (43.7%)   | 34 (47.2%)         | 11 (35.5%) |         |
| N3                       | 9 (8.7%)     | 8 (11.1%)          | 1 (3.2%)  |         |
| Unknown                  | 21 (20.4%)   | 11 (15.3%)         | 10 (32.3%) |         |
| Sub-site                 |              |                    |         | 0.057   |
| Pyriform Sinus           | 75 (72.8%)   | 51 (70.8%)         | 24 (77.4%) |         |
| Post-pharyngeal Wall     | 10 (9.7%)    | 10 (13.9%)         | 0 (0.0%)  |         |
| Post-Cricoid             | 5 (4.9%)     | 3 (4.2%)           | 2 (6.5%)  |         |
| Hypopharynx Unknown      | 13 (12.3%)   | 8 (11.2 %)         | 5 (16.1 %) |         |

**TABLE 1: Characteristics of advanced stage (III, IVA & IVB) hypopharyngeal cancer**

*ChemoRT = definitive chemoradiation therapy; RT = radiation therapy

The median follow-up was 17 months. The whole cohort of patients had a median survival of 26 months and
a five-year overall survival of 25.5%. The median survival was found to be significantly better for the surgery group as compared to the definitive chemoradiotherapy group (43 months vs. 16 months, \( p = 0.049 \)). The five-year OS was found to be significantly better for patients in the surgery group compared to the chemoradiotherapy group (41.5% vs. 18.5%, \( p = 0.049 \); Figure 2). The corresponding five-year disease-free survival (DFS) was also better for the surgery group (75.3% vs 56%; \( p = 0.029 \); Figure 3). There was no difference in five-year survival between the patients treated with 3D CRT compared to those treated with IMRT.

**FIGURE 2:** Kaplan–Meier overall survival for advanced stage hypopharyngeal cancer by treatment modality

**FIGURE 3:** Kaplan–Meier disease-free survival for advanced stage hypopharyngeal carcinoma by treatment
Multivariate Cox-regression analysis (MVA) was performed to identify the independent predictors of OS and assess potential confounding variables (Table 2). MVA revealed that chemoradiation treatment (HR = 1.82, CI: 1.00-3.29, p = 0.048) and lymph nodal status (HR = 1.27, CI: 1.00-1.62, p = 0.047) were associated with an increased risk of mortality. Variables including age, gender, ethnicity, smoking status, T staging, and subsites were not predictors for survival. Only nodal status was found to be a predictor of DFS (HR = 1.80, CI: 1.13-2.86, p = 0.013) on multivariate analysis.

| Overall Survival (OS) | Disease-free Survival (DFS) |
|-----------------------|------------------------------|
| **HR (95% CI)**       | **P-value**                  | **HR (95% CI)** | **P-value** |
| Gender/Sex            | 1.47 (0.60-3.58)             | 0.387           | 2.59 (0.71-9.41) | 0.147 |
| Age                   | 0.67 (0.34-1.32)             | 0.251           | 0.54 (0.23-1.27) | 0.164 |
| Ethnicity             | 1.21 (0.71-2.03)             | 0.472           | 0.84 (0.38-1.86) | 0.671 |
| Smoking Status        | 1.11 (0.45-2.70)             | 0.818           | 0.31 (0.70-1.45) | 0.140 |
| Alcohol Status        | 0.82 (0.45-1.50)             | 0.530           | 0.82 (0.36-1.86) | 0.636 |
| Overall Stage III vs IV| 0.93 (0.42-2.07)             | 0.867           | 0.24 (0.02-2.02) | 0.191 |
| T classification       | 1.12 (0.93-1.34)             | 0.218           | 1.13 (0.84-1.51) | 0.393 |
| N classification       | 1.27 (1.00-1.62)             | 0.047           | 1.80 (1.13-2.86) | 0.013 |
| Subsites               | 0.95 (0.40-2.22)             | 0.908           | 0.82 (0.59-1.14) | 0.243 |
| Treatment              | 1.82 (1.00-3.29)             | 0.048           | 1.63 (0.64-4.14) | 0.297 |

**TABLE 2: Multivariable Cox Regression for OS and DFS**

*ChemoRT = definitive chemoradiation therapy; RT = radiation therapy; HR = hazard ratio; CI = confidence interval; OS = overall survival; DFS = disease-free survival

Discussion

Hypopharyngeal cancer is a rare malignancy of the head and neck region, contributing to only 3% to 5% of all the head and neck cancers [1-2]. Our data is consistent with the literature, with hypopharyngeal cancer constituting 4% of all the patients in the head and neck cancer database of our institution. Patients with hypopharyngeal squamous cell carcinoma are mostly males with a known history of tobacco (90%) and heavy alcohol use (50%) [18].

The National Cancer Database (NCDB) data shows that patients with hypopharyngeal cancer are, on average, 63 years old, 75% male, and Caucasian over 70% of times. In contrast to this, our patient cohort consisted of mainly African American patients (59.2%), likely due to the demographics of the region. In our patient cohort, 96% of the patients presented with advanced-stage disease (stage III & IV), as compared to 70% to 85% reported in the literature [4-6]. This difference is likely due to disparities in access to care.

Hypopharyngeal cancers usually have a locally aggressive pattern and are reported to have the worst prognosis among all the head and neck cancer sites [4]. The patients with advanced-stage hypopharyngeal cancer have five-year OS, ranging from 25% to 41% [21]. There are few single-institution experiences where they report a higher five-year overall survival of 62% and 66% [12,16]. Compared to this data, our patients had a median survival of 26 months and the five-year overall survival of 25.5%, which is consistent with the majority of literature.

Historically, surgery followed by adjuvant radiation has been the standard-of-care for patients presenting with advanced disease. The European Organization for Research and Treatment of Cancer (EORTC) 24891 trial proved that laryngeal preservation using chemoradiation treatment is an equally effective treatment, thus became the standard of care [19-20]. Another randomized control trial by Beavillain et al. reported a contradicting result in which they found improved five-year overall survival (37% vs. 19%, p = 0.04) and local control (65% vs. 39%, p = 0.01) in the surgery arm [6]. Of note, both these trials used induction chemotherapy followed by radiation treatment as the strategy for laryngeal preservation, instead of concurrent chemoradiotherapy. Retrospective reviews have also reported conflicting results. A retrospective single-institution review by Harris et al. identified a clinical improvement in five-year survival with the use of surgery followed by adjuvant treatments over definitive concurrent chemoradiation treatment but was not statistically significant (66.3% vs. 41.3%, p = 0.09) [12]. A population-based experience from the Netherlands
reported that surgical management and laryngeal preservation treatment had equivalent survival for patients with T3 disease (40% vs. 39%, \( p = 0.475 \)), but not for patients with T4 disease (29% vs. 24%, \( p = 0.039 \)) [22]. Contrary to this, Hall et al., Lee et al., Zelefsky et al., Iwae et al., and Lajtman et al. reported an equivalent survival outcome between surgical or non-surgical management for advanced hypopharyngeal cancer [13-15,17,23]. SEER (Surveillance, Epidemiology and, End Results) database analysis did not find a difference in three-year survival for T4 patients between surgical and non-surgical treatments (29.9% vs. 26.1%, \( p = 0.439 \)) [24]. A single-institution experience from Taiwan reported equivalent survival among patients who received laryngeal preservation or operative management [25]. Two systematic reviews have compiled the data on laryngeal preservation for hypopharyngeal cancer and reported that laryngeal preservation offered equivalent survival as surgical treatments [9-10]. In our study, we found that surgical management resulted in an improved five-year overall survival as compared to chemoradiotherapy (41.5% vs. 18.5%, \( p = 0.049 \)). This difference is likely due to the inclusion of laryngeal preservation patients and unresectable patients together in the chemoradiotherapy group.

Limitations of our study include its retrospective nature and a modest number of patients, which leads to selection bias in the patient cohorts. We were not able to account for the confounding factors, including medical comorbidities, and that might have contributed to the observed survival differences. These patients are treated over the last 25 years, during which radiation techniques, surgical techniques, and systemic therapy have evolved. These changes might be contributing to the results that we observed. Some of the follow-up data are missing, including salvage treatments and causes of death. So, the differences in the survival between the two different treatment groups should be interpreted within the context of the limitations of a non-randomized retrospective study.

Conclusions
In our institutional experience over the last 25 years, the majority of the hypopharyngeal carcinoma patients presented with advanced-stage disease. The five-year overall survival rates of our patient cohort were around 25%, which is consistent with the literature. From our analysis, surgical management was found to have better survival compared to definitive chemoradiotherapy. Further research was warranted for early detection and better treatment to improve the cure rate in hypopharyngeal carcinoma patients.

Additional Information
Disclosures

Human subjects: Consent was obtained by all participants in this study. University of Mississippi Medical Center issued approval protocol # 2010-0252. IRB file # 2010-0252 Outcomes following treatment for Head and Neck Your amendment was reviewed and approved by the Expedited Review process on 11/11/2019. Please note the following information about your approved research protocol: Protocol Approval period: 11/11/2019-07/21/2020 Approved Enrollment #: 10000 Performance stites: UMMC.

Consent was obtained by all participants in this study. University of Mississippi Medical Center issued approval protocol # 2010-0252. IRB file # 2010-0252 Outcomes following treatment for Head and Neck Your amendment was reviewed and approved by the Expedited Review process on 11/11/2019. Please note the following information about your approved research protocol: Protocol Approval period: 11/11/2019-07/21/2020 Approved Enrollment #: 10000 Performance stites: UMMC. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICME uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Hoffman HT, Karnell LH, Shah JP, et al.: Hypopharyngeal cancer patient care evaluation. Laryngoscope. 1997, 107:1005-1017. 10.1097/00005537-199708000-00001
2. Chan JY, Wei W: Current management strategy of hypopharyngeal carcinoma. Auris Nasus Larynx. 2015, 40:2-6. 10.1016/j.anl.2011.11.009
3. Juloori A, Royman SA, Geiger JL, et al.: Definitive chemoradiation in locally advanced squamous cell carcinoma of the hypopharynx: long-term outcomes and toxicity. Anticancer Res. 2018, 38:3543-3549. 10.21875/anticanres.12626
4. Chen Y-Y, Tsai Y-T, Tsai M-S, et al.: Treatment outcomes of locally advanced hypopharyngeal squamous cell carcinoma. Therapeutic Radiology and Oncology. 2018, 2: 10.21037/tro.2018.05.02
5. Slotman BJ, Kralendijk JH, Snow GB, Tiwari RM, Karim AB: Surgery and postoperative radiotherapy and radiotherapy alone in T3-T4 cancers of the piriform sinus. Treatment results and patterns of failure. Acta Oncol. 1994, 33:55-60. 10.3109/02841869409098576
6. Beaulavilain C, Mahé M, Boudrin S, et al.: Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope. 1997, 107:648-653. 10.1097/00005537-199705000-00017
7. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th Edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010, 17:1471-1474. 10.1245/s10434-010-0985-4
8. Amin MB, Edge S, Greene F, et al.: AJCC Cancer Staging Manual (8th edition) . Amin MB (ed): Springer International Publishing. 2017.
9. Habib A: Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol. 2018, 132:385-400. 10.1017/S0022215118000555
10. Denaro N, Russi EG, Lefebvre JL, Merlano MC: A systematic review of current and emerging approaches in the field of larynx preservation. Radiother Oncol. 2014, 110:16-24. 10.1016/j.radonc.2013.08.016

11. Elias MM, Hilgers FJ, Keus RB, Gregor RT, Hart AA, Balm AJ: Carcinoma of the pyriform sinus: a retrospective analysis of treatment results over a 20-year period. Clin Otolaryngol Allied Sci. 1995, 20:249-255. 10.1111/j.1365-2273.1995.tb01860.x

12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Head and Neck Cancers. Version 2.2019. Accessed: October 1, 2019: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf

13. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase Ill trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996, 88:890-899. 10.1093/jnci/88.13.890

14. Harris B: Primary surgery vs chemoradiation treatment of advanced stage hypopharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2015, 10.1001/jamaoto.2015.2794

15. Hall SF, Groome PA, Irish J, O’Sullivan B: Radiotherapy or surgery for head and neck squamous cell cancer: establishing the baseline for hypopharyngeal carcinoma? Cancer. 2009, 115:5711-5722. 10.1002/cncr.24635

16. Lee MS, Ho HC, Hsiao SH, Hwang JH, Lee CC, Hung SK: Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol. 2008, 128:105-109. 10.1080/00016480701387116

17. Zelefsky MJ, Kraus DH, Pfister DG, et al.: Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck. 1996, 18:5-405. 10.1007/s10147-017-1151-9

18. Juloor A, Koyfman S A, Geiger JL, et al.: Definitive chemoradiation in locally advanced squamous cell carcinoma of the hypopharynx: Long-term Outcomes and Toxicity. Anticancer Res. 2018, 38:3543-3549. 10.21873/anticancer.12626

19. Iwae S, Fujii M, Hayashi R, et al.: Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy. Int J Clin Oncol. 2017, 22:1001-1008. 10.1007/s10147-017-1151-9

20. Garneau JC, Bakst RL, Miles BA: Hypopharyngeal cancer: A state of the art review. Oral Oncol. 2018, 86:244-250. 10.1016/j.oraloncology.2018.09.025

21. Kılıç S, Kılıç SS, Hsieh WD, Eloy JA, Baredes S, Woo Park RC, Mahmoud O: Radiotherapy modality as a predictor of survival in hypopharyngeal cancer. Head Neck. 2018, 40:2441-2448. 10.1002/hed.25360

22. Petersen JF, Timmermans AJ, van Dijk BAC, et al.: Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. Eur Arch Otorhinolaryngol. 2018, 275:181-189. 10.1007/s00405-017-4766-6

23. Lajtman Z, Manestar D: A comparison of surgery and radiotherapy in the management of advanced pyriform fossa carcinoma. Clin Otolaryngol Allied Sci. 2001, 26:59-61. 10.1046/j.1365-2275.2001.00430.x

24. J KY: Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population based study. Cancer Medicine. 2018, 10.1002/cam4.1811

25. Chang MF, Wang HM, Kang CJ, et al.: Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary—an experience in Taiwan. Radiat Oncol. 2010, 5:91. 10.1186/1748-717X-5-91